P391: Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Feagan, B.(2,3);Gibble, T.H.(4);Keohane, A.(4);Eastman, W.(4);Traxler, K.(4);Schreiber, S.(5);Jairath, V.(6);Armuzzi, A.(7);
(1)Icahn School of Medicine- Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Alimentiv- Inc, Clinical research, London- Ontario, Canada;(3)Western University, Gastroenterology, London- Ontario, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)University Hospital Schleswig-Holstein- Kiel University-, Clinic for Internal Medicine I, Kiel, Germany;(6)University Hospital, Department of Medicine, London- Ontario, Canada;(7)Humanitas Research Hospital- Rozzano, Gastroenterology, Milan, Italy;
P392: Risk factors for postoperative recurrence after ileocolic resection for Crohn's Disease: long-term results from a population-based cohort.ECCO’23 CopenhagenYear: 2023
Authors: van Renterghem, A.(1)*;van der Holst, A.(1);van Kuijk, S.(2);Pierik, M.(3);Belgers, E.(4);Romberg-Camps, M.(5);Jeuring, S.(3);Demandt, D.(1);Stassen, L.(1);
(1)Maastricht University Medical Centre +, Surgery, Maastricht, The Netherlands;(2)Maastricht University Medical Centre +, Epidemiology, Maastricht, The Netherlands;(3)Maastricht University Medical Centre +, Gastroenterology, Maastricht, The Netherlands;(4)Zuyderland Medical Centre, Surgery, Heerlen, The Netherlands;(5)Zuyderland Medical Centre, Gastroenterology, Heerlen, The Netherlands;
P393: Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTIONECCO’23 CopenhagenYear: 2023
Authors: Loveikyte, R.(1)*;de Haas, A.(2);Oortwijn, A.(3);Eskens, B.(3);Jamoul, C.(4);Muller, K.(4);van der Meulen-de Jong, A.(5);
(1)Leiden University Medical Center LUMC, Gastroenterology and Hepatology, Leiden, The Netherlands;(2)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(3)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(4)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(5)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;
P394: Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre studyECCO’23 CopenhagenYear: 2023
Authors: Berghog, J.(1)*;Hermansson, M.(2);Risto, A.(3);Strömbäck, J.(4);Unger, D.(4);Gustafsson, H.(5);Hagavall, M.(6);Landerholm, K.(7);Buchwald, P.(8);Nordenvall, C.(9);Myrelid, P.(3);Block, M.(2);
(1)Institute of Clinical Sciences- Sahlgrenska Academy Gothenburg University- Gothenburg- Sweden, Department of Surgery- Sahlgrenska University Hospital/ Östra- Gothenburg- Sweden, Göteborg, Sweden;(2)Institute of Clinical Sciences- Sahlgrenska Academy Gothenburg University- Gothenburg- Sweden, Department of Surgery- Sahlgrenska University Hospital/Östra- Gothenburg- Sweden, Göteborg, Sweden;(3)Department of Clinical and Experimental Medicine- Linköping University- Linköping- Sweden, Department of Surgery- Linköping University Hospital- Linköping- Sweden, Linköping, Sweden;(4)Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Stockholm, Sweden;(5)Department of Surgery- Skåne University Hospital- Malmö- Sweden, Department of Surgery- Skåne University Hospital- Malmö- Sweden, Malmö, Sweden;(6)Department of Surgery- Ryhov county hospital- Jönköping- Sweden, Department of Surgery- Ryhov county hospital- Jönköping- Sweden, Jönköping, Sweden;(7)Department of Biochemical and Clinical Sciences- Linköping University- Linköping- Sweden, Department of Surgery- Ryhov county hospital- Jönköping, Jönköping, Sweden;(8)Department of Clinical Sciences Malmö- Lund University- Lund- Sweden, Department of Surgery- Skåne University Hospital- Malmö- Sweden, Malmö, Sweden;(9)Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Department of Pelvic Cancer- colorectal surgery unit- Karolinska University Hospital- Stockholm- Sweden, Stockholm, Sweden;Swedish Organization for the study of IBD (SOIBD)
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndromeECCO’23 CopenhagenYear: 2023
Authors: Kaku, K.(1)*;Sato, T.(1);Takeuchi, J.(2);Uchino , M.(3);Fujihira, Y.(1); Shimizu, K.(1);Yokoyama, K.(1);Yagi , S.(1);Takashima, Y.(1);Ikenouchi, M.(1);Kojima, K.(1);Kawai, M.(1); Nagase , K.(1);Kamikozuru, K.(1);Yokoyama , Y.(1);Takagawa, T.(1); Ikeuchi, H.(3);Watanabe, K.(1);Shinzaki , S.(1);
(1)Hyogo Medical University, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Hyogo, Japan;(2)Hyogo Medical University, Department of Clinical Epidemiology, Hyogo, Japan;(3)Hyogo Medical University, Division of Surgery- Department of Inflammatory Bowel Disease, Hyogo, Japan;
P396: Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;Grova, M.(1);Mocciaro, F.(2);Di Mitri, R.(2);Privitera, A.C.(3);Distefano, M.E.(3);Vitello, A.(4);Camilleri, S.(4);Ferracane, C.(5);Pluchino, D.(5);Belluardo, N.(6);Giangreco, E.(6);Fries, W.(7);Viola, A.(7);Cappello, M.(8);Amato, L.(8);Bertolami, C.(9);Ventimiglia, M.(10);Renna, S.(1);Casà, A.(1);De Vivo, S.(1);Orlando, A.(1);
(1)Villa Sofia-Cervello Hospital, IBD Unit, Palermo, Italy;(2)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy;(3)Cannizzaro Hospital, IBD Unit, Catania, Italy;(4)S. Elia- Raimondi Hospital, Gastroenterology and Endoscopy Unit, Caltanissetta, Italy;(5)Vittorio Emanuele Hospital, Gastroenterology Unit, Catania, Italy;(6)Guzzardi Hospital, Gastroenterology Unit, Vittoria, Italy;(7)G. Martino Hospital, IBD Unit, Messina, Italy;(8)University of Palermo, Gastroenterology & Hepatology Section- Promise, Palermo, Italy;(9)Papardo Piemonte Hospital, Gastroenterology Unit, Messina, Italy;(10)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Rome, Italy;Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
P397: Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)ECCO’23 CopenhagenYear: 2023
Authors: Lasa, J.(1)*;Nazario, E.(2);Zubiaurre, I.(2);Rausch, A.(2);Hermida, R.(3);Cassella, F.(4);Marzullo, S.(4);Suarez Pellegrino, A.(5);Deborah, B.(5);Toro, M.(5);Novillo, A.(6);Omodeo, J.(6);Tirado, P.(7);Bellicoso, M.(7);Olivera, P.(8);Balderramo, D.(9);Torello, R.(9);Chiaraviglio, L.(9);Scacchi, A.(3);Linares, M.(10);Gonzalez, R.(11);Bentolila, F.(11);Lubrano, P.(12);Quintero, O.(10);De Paula, J.(13);Gonzalez Sueyro, R.(13);Sanchez, B.(13);Fuxman, C.(14);Velazquez , A.(15);
(1)CEMIC, Gastroenterology, Buenos Aires, Argentina;(2)Hospital Británico, Gastroenterology, Buenos Aires, Argentina;(3)Hospital Churruca Visca, Gastroenterology, Buenos Aires, Argentina;(4)Sanatorio Guemes, Gastroenterology, Buenos Aires, Argentina;(5)HIGEA, Gastroenterology, Mendoza, Argentina;(6)Sanatorio 9 de Julio, Gastroenterology, San Miguel de Tucumán, Argentina;(7)Inmunología Buenos Aires, Gastroenterology, Buenos Aires, Argentina;(8)Zane Cohen Centre for Digestive Diseases- Lunenfeld-Tanenbaum Research Institute- Sinai Health System, Gastroenterology, Toronto, Canada;(9)Hospital Privado, Gastroenterology, Córdoba, Argentina;(10)Hospital de Clínicas, Gastroenterology, Buenos Aires, Argentina;(11)Hospital Alemán, Gastroenterology, Buenos Aires, Argentina;(12)Sanatorio Mater Dei, Gastroenterology, Buenos Aires, Argentina;(13)Hospital Italiano, Gastroenterology, Buenos Aires, Argentina;(14)Hospital Universitario Fundación Favaloro, Gastroenterology, Buenos Aires, Argentina;(15)Hospital Universitari Fundación Favaloro, Gastroenterology, Buenos Aires, Argentina;
P398: Disease clearance: a potential target for management of patients with Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Andronic, A.M.(1)*;Toader, E.(1);
(1)"Grigore T. Popa" University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, Iasi, Romania;
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?ECCO’23 CopenhagenYear: 2023
Authors: Aksan, A.(1,2,3)*;Mangold, C.(4);Stötzel, J.(1,3);Tessmer, L.(3,5);Schröder, O.(3,5);Stein, J.M.(3,5,6);
(1)Justus-Liebig University Giessen, Institute of Nutritional Science, Giessen, Germany;(2)Immundiagnostik AG, Medical Affairs, Bensheim, Germany;(3)Interdisciplinary Crohn-Colitis Centre Rhein-Main, Clinical Research, Frankfurt am Main, Germany;(4)Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany;(5)DGD Clinics Sachsenhausen, Gastroenterology/Oncology, Frankfurt am Main, Germany;(6)Goethe University Frankfurt, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany;
P400: Identifying Nutritional targets in Crohn's disease: INTICO1: a time-limited trial of exclusive enteral nutrition during adult CD remissionECCO’23 CopenhagenYear: 2023
Authors: McDonnell, M.(1,2)*;Westoby, C.(3);Sartain , S.(1);Giannasca, P.(4);Corthésy, J.(5);Grzywinski, Y.(6);Frézal, A.(5);Capt, P.(5);Cummings, F.(1);Wootton, S.(7);
(1)University Hospital Southampton, Gastroenterology, Southampton, United Kingdom;(2)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;(3)University Hospital Southampton, Department of Nutrition and Dietetics, Southampton, United Kingdom;(4)Nestle Health Science, Nestle Research, Cambridge, United States;(5)EPFL Innovation Park, Nestlé Research- Société des Produits Nestlé S.A, Lausanne, Switzerland;(6)EPFL Innovation Park, Nestlé Research- Société des Produits Nestlé S.A, Lasuanne, Switzerland;(7)University Hospital Southampton, Human Nutrition, Southampton, United Kingdom;
P401: Concomitant azathioprine treatment effects vedolizumab treatment persistence in Crohn's Disease but not in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Toruner, M.(1)*;Guvenir, T.(1);Er, R.E.(1);Soykan, I.(1);
(1)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;
P402: A Pilot Study on the Effect of Colesevelam on the Microbiome in Primary Terminal Ileal Resected Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kumar, A.(1)*;Quraishi, M.N.(2);Al-Hassi, H.O.(3);Elasrag, M.(4);Segal, J.P.(5);Jain, M.(1);Steed, H.(1);Butterworth, J.(6);Farmer, A.(7);McLaughlin, J.(8);Beggs, A.(4);Brookes, M.(1);
(1)The Royal Wolverhampton NHS Trust, Department of Gastroenterology, Wolverhampton, United Kingdom;(2)University Hospitals Birmingham NHS Foundation Trust, Department of Gastroenterology, Birmingham, United Kingdom;(3)University of Wolverhampton, Faculty of Sciences and Engineering, Wolverhampton, United Kingdom;(4)University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom;(5)Northern Hospital, Department of Gastroenterology, Victoria, Australia;(6)Shrewsbury and Telford Hospital NHS Trust, Department of Gastroenterology, Shrewsbury, United Kingdom;(7)University Hospitals of North Midlands, Department of Gastroenterology, Stoke-on-Trent, United Kingdom;(8)Salford Royal Foundation Trust, Department of Gastroenterology, Salford, United Kingdom;
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.ECCO’23 CopenhagenYear: 2023
Authors: Hajlaoui, A.(1)*;Sabbah, M.(2);Bibani, N.(2);Jlassi, H.(2);Bellil , N.(2);Lassoued, K.(2);Trad, D.(2);Gargouri, D.(2);
(1)Habib Thameur Hospital, Department of gastroenterology., tunis, Tunisia;(2)Habib thameur hospital, Department of gastroenterology, tunis, Tunisia;
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remissionECCO’23 CopenhagenYear: 2023
Authors: Mathieu, N.(1)*;Riviere, P.(2); Heluwaert, F.(3); Hébuterne, X.(4);Chupin, A.(5);Bouguen, G.(6);Vuitton, L.(7);Allez, M.(8);Montuclard, C.(9);Nachury, M.(10);Nancey, S.(11);Amélie, B.(12); Gilletta, C.(13);Abitbol, V.(14);Altwegg, R.(15);de Maissin, A.(16);Plastaras , L.(17); Ah Soune, P.(18);Boureille, A.(19);Bouhnik, Y.(20);Seksik, P.(21);Chanteloup, E.(22);marion, S.(23);Uzzan, M.(24);Andrau, P.(25);Rouillon, C.(26);Arondel, Y.(27);Peyrin Biroulet, L.(28);Laharie, D.(29);
(1)CHU Grenoble Alpes, Hepato-gastroenterology and digestive oncology department- University Hospital, Grenoble, France;(2)University Hospital of Bordeaux, Department of Gastroenterology, Bordeaux, France;(3)University Hospital of Nimes- Nimes- France, Department of Gastroenterology-, Annecy, France;(4)CHU of Nice- University Côte d'Azur-, Gastroenterology and Clinical Nutrition-, Nice, France;(5)Assistance publique-Hôpitaux de Paris AP-HP, Service de Gastro-Entérologie-, Paris, France;(6)CHU Rennes- Univ Rennes- INSERM- CIC1414- Institut NUMECAN Nutrition Metabolisms and Cancer-, Department of Gastroenterology, Rennes, France;(7)University Hospital of Besançon, Department of Gastroenterology, Besançon, France;(8)Assistance publique-Hôpitaux de Paris AP-HP- Hopital St-Louis, Service de Gastro-Entérologie-, Paris, France;(9)Valence Hospital, Department of Gastroenterology, Valence, France;(10)Institute for Translational Research in Inflammation, Universitéde Lille- Inserm- CHU Lille- U1286 - INFINITE, Lille, France;(11)Inserm U1111-CIRI- Lyon-Sud University Hospital- Hospices Civils de Lyon, Department of Gastroenterology-, Lyon, France;(12)Reims University Hospital, Department of Gastroenterology, Reims, France;(13)Toulouse University Hospital, Department of Gastroenterology, Toulouse, France;(14)Assistance publique-Hôpitaux de Paris AP-HP- Cochin Hospital, Service de Gastro-Entérologie-, Paris, France;(15)University Hospital of Montpellier, Department of Gastroenterology-, Montpellier, France;(16)CHD la Roche sur Yon Hospital, Department of gastroenterology, La Roche sur Yon, France;(17)Colmar Hospital, Department of Gastroenterology- University Hospital of Nimes, Colmar, France;(18)Toulon Hospital, Department of gastroenterology, Toulon, France;(19)Nantes University Hospital, Department of Gastroenterology, Nantes, France;(20)groupe hospitalier Ambroise Paré - Hartmann, institut des MICI, Paris, France;(21)Centre de recherche Saint-Antoine- Sorbonne Université- INSERM- APHP- Hôpital Saint-Antoine, Department of Gastroenterology, Paris, France;(22)Groupe hospitalier Saint Joseph, Depatment of gastroenterology, Paris, France;(23)Institut mutualiste Montsouris IMM, department of gastroenterology, Paris, France;(24)Beaujon Hospital- APHP- Clichy, Department of Gastroenterology, Paris, France;(25)Tarbes Hospital, Department of Gastroenterology, Tarbes, France;(26)Caen University Hospital, Department of Gastroenterology-, Caen, France;(27)centre hospitalier de Haguenau, Department of gastroenterology, Haguenau, France;(28)University Hospital of Nancy- University of Lorraine, Department of Gastroenterology and INSERM NGERE U1256, Vandoeuvre-lès-Nancy, France;(29)CHU de Bordeaux- Hôpital Haut-Lévêque-, Service d'Hépato-gastroentérologie et oncologie digestive –Universitéde Bordeaux, Bordeaux, France;
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extensionECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Afzali, A.(5);Abreu, M.T.(6);
(1)Inflammatory Bowel Disease Clinic, Medicine, Calgary, Canada;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy;(3)Atlanta Gastroenterology Associates LLC, Medicine, Atlanta, United States;(4)Bristol Myers Squibb, Clinical Research, Princeton, United States;(5)University of Cincinnati, Division of Digestive Diseases, Cincinnati, United States;(6)The University of Miami Miller School of Medicine, Medicine, Miami, United States;
P406: Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim AnalysisECCO’23 CopenhagenYear: 2023
Authors: Chatzinikolaou-, M.L.(1)*;Kifnidi, C.(2);Kokkotis, G.(1);Gatopoulou, A.(3);Michopoulos, S.(4);Soufleris, K.(5);Poulopoulos, G.(6);Theodoropoulou, A.(7);Mantzaris, G.(8);Ntelis, V.(9);Papatheodoridis, G.(10);Tzouvala, M.(11);Koutroubakis, I.E.(12);Theocharis, G.(13);Kourikou, A.(14);Christodoulou, D.(15);Grammatopoulos, A.(16);Michalopoulos, G.(17);Georgopoulos, S.(18);Akriviadis, E.(19);Vradelis, S.(20);Gkagkari, V.(4);Zampeli, E.(4);Fasoulas, K.(5);Charalampidis, M.(6);Velegraki, M.(7);Karampekos, G.(8);Viazis, N.(8);Andrianakou , G.(9);Karatzas, P.(10);Tribonias, G.(11);Zacharopoulou, E.(11);Orfanoudaki, E.(12);Tsellou, E.(2);Psyrilos, A.(2);Roussou, D.(2);Bamias, G.(1);
(1)National and Kapodistrian University of Athens- Sotiria Hospital, GI Unit- 3rd Department of Internal Medicine, Athens, Greece;(2)Takeda Hellas SA, Medical Department, Athens, Greece;(3)University Hospital of Alexandroupolis, 2nd Dept of Internal Medicine, Alexandroupolis, Greece;(4)Alexandra Hospital, GI Unit, Athens, Greece;(5)Theageneio Anticancer Hospital, Gastroenterology Department, Thessaloniki, Greece;(6)Private Practice, GI Unit, Thessaloniki, Greece;(7)Venizeleio General Hospital, Gastroenterology Department, Heraklion, Greece;(8)GHA “Evangelismos-Polykliniki” General Hospital, Gastroenterology Department, Athens, Greece;(9)“G. Gennimatas” General Hospital, Gastroenterology Department, Athens, Greece;(10)Medical School of National and Kapodistrian University of Athens- “Laikon” General Hospital, Academic Dept of Gastroenterology, Athens, Greece;(11)“Agios Panteleimon” General Hospital Nikaia-Piraeus, Gastroenterology Department, Nikaia, Greece;(12)University Hospital of Heraklion, Gastroenterology Department, Heraklion, Greece;(13)University Hospital of Patras, Gastroenterology Department, Patras, Greece;(14)Medical School- National and Kapodistrian University of Athens- Hippocration Hospital, 2nd Academic Dept of Internal Medicine- GI-Liver- Endoscopy Unit, Athens, Greece;(15)University Hospital of Ioannina, Gastroenterology Department, Ioannina, Greece;(16)“Metropolitan” Hospital, Gastroenterology Department, Faliro, Greece;(17)“Tzaneion”- General Hospital of Piraeus, Gastroenterology Department, PIraeus, Greece;(18)Athens Medical Group - Faliron, Gastroenterology Department, Faliro, Greece;(19)“Hippokratio” General Hospital of Thess., Gastroenterology Department, Thessaloniki, Greece;(20)University Hospital of Thrace, Gastroenterology Department, Alexandroupolis, Greece;
P407: Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1,2)*;Dubinsky, M.C.(3);Sands, B.E.(4);Panés, J.(5);Schreiber, S.(6);Reinisch, W.(7);Feagan, B.G.(8);Danese, S.(9);Yarur, A.(10);D'Haens, G.(11);Goetsch, M.(12);Wosik, K.(13);Wu, J.(14);Modesto, I.(15);McDonnell, A.(16);Bartolome, L.(17);Rabbat, C.J.(18);Vermeire, S.(19);
(1)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(2)Groupe Hospitalier privé Ambroise Paré - Hartmann, Paris IBD Center, Neuilly sur Seine, France;(3)Feinstein IBD Center- Icahn School of Medicine, Gastroenterology, New York- New York, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York- New York, United States;(5)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;(6)Kiel University, University Hospital Schleswig-Holstein- Department Internal Medicine I, Kiel, Germany;(7)Medical University of Vienna, Department of Internal Medicine III- Division Gastroenterology and Hepatology, Vienna, Austria;(8)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(9)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(10)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(11)University of Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(12)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Kirkland- Quebec, Canada;(14)Pfizer Inc, Global Product Development, Groton- Connecticut, United States;(15)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(16)Pfizer- Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(17)Pfizer Inc, Global Health Economics & Outcomes Research- Inflammation & Immunology, New York- New York, United States;(18)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(19)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;
P408: Dual therapy with vedolizumab and tofacitinib in refractory ulcerative colitis patients – single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Kolar, M.(1);Kastylova, K.(1);Lukas, M.(1);Duricova, D.(1);Hruba, V.(1);Machkova, N.(1);Cerna, K.(1);Jirsa, J.(1);Kubickova, K.(1);Vojtechova, G.(1);Lukás, M.(1)*;
(1)ISCARE a.s., IBD Clinical and Research Center, Prague, Czech Republic;
P409: Using antidepressants for refractory symptoms of Inflammatory Bowel Disease: a prospective service evaluationECCO’23 CopenhagenYear: 2023
Authors: Moulton, C.(1)*;Avery, P.(2);Hart, A.(3);
(1)St Mark's Hospital, Psychological Medicine Unit, London, United Kingdom;(2)St Mark's Hospital, Inflammatory Bowel Disease Nursing Team, London, United Kingdom;(3)St Mark's Hospital, St Mark's Academic Institute, London, United Kingdom;
P410: Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDAECCO’23 CopenhagenYear: 2023
Authors: Gargallo-Puyuelo, C.(1)*;Ricard, E.(2);Iborra, M.(3);Iglesias-Flores, E.(4);Vera Mendoza, I.(5);De Francisco García, R.(6);Calafat Sard, M.(7);Minguez, M.(8);Lopez- San Roman, A.(9);Taxonera, C.(10);Guardiola, J.(11);Barrio, J.(12);Laredo, V.(13);De Castro, L.(14);Gisbert, J.(15);García-Lopez, S.(16);García Planella, E.(17);Martín Arranz, D.(18);Calvet, X.(19);Merino, O.(20);Sierra, M.(21);Marquez, L.(22);Madero, L.(23);Varela, P.(24);Carpio, D.(25);Esteve, M.(26);Rivero, M.(27);Ramos , L.(28);Sicilia, B.(29);Lorente POyatos, R.(30);Marin, I.(31);Monfort, D.(32);Navarro, M.(33);VEga, P.(34);Hinojosa, J.(35);Tardillo, C.(36);García Sepulcre, M.F.(37);Barreiro, M.(38);Domenech, E.(7);Gomollón, F.(39);
(1)Hospital Clínico Universitario Lozano Blesa, Gastroenterology., Zaragoza, Spain;(2)H. Clínic Barcelona, Gastroenterology, Barcelona, Spain;(3)Hospital Universitario La Fe de Valencia, Gastroenterology, Valencia, Spain;(4)H. Reina Sofía, Gastroenterology, Cordoba, Spain;(5)H.U. Puerta de Hierro, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(7)H.U. Germans Trias i Pujol, Gastroenterology, Barcelona, Spain;(8)H. Clínico de Valencia, Gastroenterology, Valencia, Spain;(9)H. Ramón y Cajal, Gastroenterology, Madrid, Spain;(10)Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain;(11)H.U. Bellvitge, Gastroenterology, Bellvitge, Spain;(12)Hospital Rio Hortega, Gastroenterology, Valladolid, Spain;(13)Hospital Ernest LLuch, Gastroenterology, Calatayud, Spain;(14)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(15)Hospital de La Princesa, Gastroenterology, Madrid, Spain;(16)Hospital Universitario Miguel SErvet, Gastroenterology, Zaragoza, Spain;(17)H. de la Sta Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(18)H. La Paz, Gastroenterology, Madrid, Spain;(19)Hospital de Sabadell, Gastroenterology, Sabadell, Spain;(20)Hospital de Cruces, Gastroetnerology, Bilbao, Spain;(21)Complejo Asistencial Universitario de León, Gastroenterology, Leon, Spain;(22)H. Del Mar, Gastroenterology, Barcelona, Spain;(23)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(24)H. Cabueñes, Gastroenterology, Gijon, Spain;(25)Complexo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain;(26)H. Mútua Terrassa, Gastroenterology, Barcelona, Spain;(27)H. U. Marques de Valdecilla, Gastroenterology, Santander, Spain;(28)H.U. Canarias, Gastroenterology, Tenerife, Spain;(29)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(30)H. General de Ciudad Real, Gastroenterology, Ciudad REal, Spain;(31)H.G.U. Gregorio Marañón, Gastroenterology, Madrid, Spain;(32)Consorci Sanitari de Terrassa, Gastroenterology, Terrasa, Spain;(33)H. Moisès Broggi, Gastroenterology, San JOan Despi, Spain;(34)Complexo H. Universitario de Ourense, Gastroenterology, Ourense, Spain;(35)H. Manises, Gastroenterology, Manises, Spain;(36)H. Nuestra Sra. de la Candelaria, Gastroenterology, Tenerife, Spain;(37)H.G.U. Elche, Gastroenterology, Elche, Spain;(38)H.U. de Santiago, Gastroenterology, Santiago de Compostolea, Spain;(39)Hospital Clínico Universtario Lozano Blesa, Gastroenterology, Zaragoza, Spain;on behalf of the ENEIDA Registry of GETECCU